Latest News
Conference Coverage
Gut microbiome dysregulation implicated in OCD
SAN FRANCISCO - Novel gut-brain axis findings open a new research portal for patients with obsessive-compulsive disorder.
Conference Coverage
Hoarding disorder patients deem few treatments as acceptable
SAN FRANCISCO – Pharmacotherapy works faster than CBT for some hoarding disorder patients and addresses comorbid psychiatric symptoms.
Feature
Medicaid reform: Work-based waivers may not fly
High mandatory premiums, cost sharing, lifetime limits, drug testing move Medicaid from a health care program to a work program, advocates argue...
Feature
CMS market stabilization efforts useless without subsidies
President Trump has threatened to withhold insurer subsidies in an effort to bring Congressional Democrats to the health care negotiation table....
Conference Coverage
Intervention may help stem weight gain tied to antipsychotics
SAN DIEGO – A 12-month behavioral intervention program leads to lower waist circumference among obese veterans taking antipsychotics.
Conference Coverage
MedPAC: Medicare Part B drug payment cuts, shared savings could save $5 billion
Reducing the amount physicians are paid for drugs administered in their offices and introducing shared savings could save Medicare up to $5...
From the Journals
Lifetime headache, suicide attempts may be linked in older patients
In elderly patients, an association is found between a risk of lifetime headache and lifetime suicide attempts.
Conference Coverage
Gotta catch ’em all: Is Pokémon Go an intervention for schizophrenia?
SAN DIEGO – Could playing Pokémon Go improve symptoms in patients with schizophrenia?
From the Journals
Young patients with first-episode psychosis face far higher mortality risk
Insured young patients with first-episode psychosis have a mortality risk that is 24 times higher than that of their peers in the general...
Conference Coverage
Evidence for medical marijuana largely up in smoke
SAN DIEGO – Despite the popularity of medical marijuana, robust evidence for its use is limited or nonexistent for most medical conditions.
FDA/CDC
FDA approves deutetrabenazine for Huntington’s-associated chorea
Deutetrabenazine is only the second product approved to treat Huntington’s in any capacity, and it is the first in nearly a decade.